Please login to the form below

Not currently logged in
Email:
Password:

Otezla

This page shows the latest Otezla news and features for those working in and with pharma, biotech and healthcare.

FDA turns down Celgene’s filing for multiple sclerosis drug

FDA turns down Celgene’s filing for multiple sclerosis drug

of Crohn’s disease candidate GED-0301, and lacklustre data for psoriasis therapy Otezla (apremilast) in ulcerative colitis.

Latest news

  • Shaky mid-stage data won’t halt Celgene’s plans for Otezla Shaky mid-stage data won’t halt Celgene’s plans for Otezla

    year. Otezla (apremilast) is already approved to treat moderate-to-severe plaque psoriasis and has become a blockbuster in that indication, bringing in $1.28bn in sales last year. ... A higher proportion of patients taking Otezla at a dose of 30mg twice

  • Celgene pays $300m upfront for immunology start-up Delinia Celgene pays $300m upfront for immunology start-up Delinia

    DEL106 is due to start clinical trials in 2018. Celgene's first foray into the immunology and inflammation sector came with psoriasis blockbuster Otezla (apremilast), and it has a string of ... Otezla continued its fast growth trajectory with sales of

  • FDA green light for Pfizer's eczema drug FDA green light for Pfizer's eczema drug

    In 2014, Celgene gained FDA approval for its PDE4 inhibitor Otezla (apremilast) for psoriasis, and has completed a proof-of-concept trial in eczema.

  • Leo Pharma’s Enstilar approved by FDA Leo Pharma’s Enstilar approved by FDA

    The new approval means that Enstilar will now compete with other oral drugs for psoriasis such as Celgene's Otezla (apremilast) as well as Pfizer's Enbrel (etanercept), which is coming

  • NICE turns down Celgene's Otezla once again NICE turns down Celgene's Otezla once again

    A final decision on the use of Otezla in psoriatic arthritis is due in October. ... The company is also developing Otezla for rheumatoid arthritis, Behcet's disease, atopic dermatitis and ulcerative colitis.

More from news
Approximately 6 fully matching, plus 13 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    Elsewhere, Celgene has seen large growth in 2017 (46%) - driven by sales of Otezla, the first oral small molecule to be approved for psoriasis and psoriatic arthritis.

  • Building a business that is lean and specialised Building a business that is lean and specialised

    This has been in the pipeline for some time and will face its first major sales and marketing test in Europe with the anticipated launch next year of Otezla (apremilast) for

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Infographic: RA Perceptions

    The greatest levels of familiarity and interest were reported for novel small molecules such as Celgene’ s Otezla (apremilast) and Pfizer’ s Xeljanz (tofacitinib), which both offer a new oral alternative ... Of the physicians who were familiar with

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics